Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

Alexandria University20 enrolled

Overview

This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Injury of the optic nerve or optic neuropathy is one of the most common causes of vision loss. This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Optic Neuropathy

Interventions

erythropoietinDRUG

Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with late stage optic neuropathy (1 month to 12 months after onset of optic neuropathy due to late referral of the cases) Exclusion Criteria: * Patients with perforating ocular injuries were excluded.

Locations (1)

Alexandria Faculty of Medicine

Alexandria, Egypt

Outcomes

Primary Outcomes

Assessment of visual acuity

Visual acuity using appropriate charts for assessment then convert into log of the minimum angle of resolution (logMAR) units to provide a numeric scale of visual acuity

Time frame: 3 months

Flash visual-evoked potentials

Flash VEP to detect amplitude reduction and latency in the optic nerve.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.